On September 27, 2023 NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, reported that it will present development progress of its main asset, NT-I7 (efineptakin alfa), across two posters at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) annual meeting, to be held in San Diego, November 1-5, 2023 (Press release, NeoImmuneTech, SEP 27, 2023, View Source [SID1234635475]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NIT presentations at the 2023 SITC (Free SITC Whitepaper) Annual Meeting:

Primary Author

Abstract Title

Presentation Details

Lee, M

NT-I7 and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that favors anti-tumor efficacy in combination with checkpoint inhibitors

• Abstract #816

• Nov 4, 2023

Naing, A

NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors

• Abstract #652

• Nov 4, 2023

About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

On September 27, 2023 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, reported that an abstract highlighting pre-clinical data on its CRB-601 anti-aVb8 integrin monoclonal antibody has been accepted for presentation as a poster at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), to be in San Diego, CA November 1-5, 2023 (Press release, Corbus Pharmaceuticals, SEP 27, 2023, View Source [SID1234635474]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Details

Abstract Number:

1388

Title:

CRB-601, an integrin αvβ8 blocking antibody entering Phase I: pre-clinical and translational biomarkers for indication selection.

Authors:

Vaishali Shinde, Daqing Wang, Danish Memon, Maneesh Singh, James Rindone, Rodney Carter, B.S, Naomi Muse, MBA, Ian Hodgson, PhD, Andrew Kolodziej and Rachael Brake.

Session Date:

Saturday November 4

Presentation Time:

9:00am to 8:30pm PT

CRB-601 is a potent and selective integrin αvβ8 blocking monoclonal antibody that can overcome tumor immune exclusion and enhance the activity of immune checkpoint inhibitors in vivo. The IND submission for CRB-601 is anticipated in Q4 2023, and the Company expects to enroll the first patient in its Phase 1 study in the first half of 2024.

The CRB-601 abstract will be available on the SITC (Free SITC Whitepaper) website as of Oct. 31, 2023, and the poster will be made available on the Company website following the presenation.

On September 27, 2023 Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, reported the presentation of 6 abstracts featuring its Lunit SCOPE suite at the upcoming SITC (Free SITC Whitepaper) 2023 (Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2023) Annual Meeting, scheduled to take place from November 1 to November 5, in San Diego, California (Press release, Lunit, SEP 27, 2023, View Source [SID1234635473]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This year’s posters span a spectrum of research, from predicting treatment outcomes in non-small cell lung cancer (NSCLC) to examining immune responses in breast cancer subtypes, utilizing the Lunit SCOPE suite.

The highlighted abstracts for SITC (Free SITC Whitepaper) 2023 include:

By analyzing the tumor microenvironment (TME) with Lunit SCOPE IO, one study explores the treatment response of non-small cell lung cancer (NSCLC) patients with EGFR mutations to immune checkpoint inhibitors (ICI) after acquiring resistance to EGFR tyrosine kinase inhibitors (TKI).
Lunit investigates the distribution of tumor-infiltrating lymphocytes (TIL) in triple-negative breast cancer (TNBC) subtypes and their association with driver mutations, shedding light on the complexities of TNBC treatment response.
Lunit delves into the relationship between methylation and cancer immunogenicity across multiple cancer types.
A study examines the influence of tumor fragmentation index (TFI) and fibroblast infiltration on inflammatory cytokines, and lymphocyte maturation in the tumor microenvironment across various carcinoma cancer types.
Lunit introduces an innovative approach to assess immune phenotype (IP) in tumor tissue using AI-powered analysis of PD-L1 IHC whole-slide images.
An additional presentation provides updated safety and efficacy results for a novel PD-1 (programmed cell death 1) agent, assessed by Lunit SCOPE IO.
"We are truly excited to showcase the capabilities of Lunit SCOPE products in assessing pathology data, improving our ability to identify responsive patients and understand cancer biology," said Brandon Suh, CEO of Lunit. "These study results promise to advance our understanding of the tumor microenvironment, paving the way for increasingly tailored and more effective cancer therapies."

Visit Lunit’s booth at SITC (Free SITC Whitepaper) 2023 at Booth 227 to learn more about these pioneering studies. To schedule a meeting with the Lunit team, please reach out to [email protected].

On September 27, 2023 Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, reported that it will present five programs at the 2023 Society of Immunology in Cancer Annual Meeting (SITC 2023) to be held in San Diego from November 1-5, 2023 (Press release, Antengene, SEP 27, 2023, View Source [SID1234635472]). As the world’s largest and most anticipated gathering in the field of immuno-oncology, the SITC (Free SITC Whitepaper) Annual Meeting is designed to promote scientific exchanges and cooperation for improving treatment outcomes for cancer patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations feature five Antengene’s clinical and preclinical programs, including two clinical programs, the anti-CD24 monoclonal antibody ATG-031 and the PD-L1/4-1BB bispecific antibody ATG-101; two preclinical programs, the LILRB4 antagonist antibody ATG-034 and the GPRC5D/CD3 T-cell engager ATG-021; as well as the proprietary novel AnTenGager platform.

Details of those poster presentations
ATG-031(anti-CD24 monoclonal antibody)
Title: The preclinical characterization and translational research of ATG-031, a first-in-class humanized anti-CD24 antibody, for the treatment of solid tumors and hematological malignancies
Abstract: 1337
Date: November 3, 2023
Time: 9:00 AM – 7:00 PM Pacific Time; 0:00 AM – 10:00 AM Beijing Time, November 4, 2023

ATG-101(PD-L1/4-1BB bispecific antibody)
Title: Single-cell RNA sequencing reveals the positive feedback activation loop between T and dendritic cells induced by PD-L1x4-1BB bispecific antibody
Abstract: 1112
Date: November 4, 2023
Time: 9:00 AM – 8:30 PM Pacific Time; 0:00 AM – 11:30 AM Beijing Time, November 5, 2023

ATG-034 (LILRB4 antagonist antibody)
Title: Antibody targeting a specific epitope of LILRB4 induces potent ADCC/ADCP effect against leukemia cells
Abstract: 1391
Date: November 3, 2023
Time: 9:00 AM – 7:00 PM Pacific Time; 0:00 AM – 10:00 AM Beijing Time, November 4, 2023

ATG-021 (GPRC5D/CD3 T-cell engager)
Title: ATG-021, a novel 2+1 CD3-based T-cell engager (TCE) targeting GPRC5D, demonstrates potent in vivo anti-tumor efficacy with low cytokine release
Abstract: 1191
Date: November 3, 2023
Time: 9:00 AM – 7:00 PM Pacific Time; 0:00 AM – 10:00 AM Beijing Time, November 4, 2023

AnTenGager Platform
Title: A novel "2+1" bispecific T cell engager platform, enables enhanced anti-tumor activity with reduced risk of CRS
Abstract: 1190
Date: November 4, 2023
Time: 9:00 AM – 8:30 PM Pacific Time; 0:00 AM – 11:30 AM Beijing Time, November 5, 2023

On September 27, 2023 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage research and development biotechnology company, reported several presentations to be unveiled at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2023 taking place October 20 to 24, 2023 in Madrid, Spain, including updated clinical data showcasing the feasibility and potential of the investigational combination of KRASG12C inhibitor, adagrasib with pembrolizumab in a study of treatment naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation (Press release, Mirati, SEP 27, 2023, View Source [SID1234635469]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Adagrasib is the first targeted KRASG12C inhibitor to show promising efficacy and early signs of durability in combination with an immune checkpoint inhibitor in the front line setting," said Alan Sandler, M.D. chief medical officer, Mirati Therapeutics. "Based on this compelling data, we plan to initiate enrollment in a global Phase 3 study in the fourth quarter evaluating adagrasib in combination with pembrolizumab in patients with KRAS G12C -mutated NSCLC with PD-L1 ≥50% with the hope of providing a better treatment option for these patients."

Presentation Title: KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Author: Marina C. Garassino
Abstract Number: 5053
Session: Proffered Paper session – NSCLC, metastatic
Presentation Date/Time: Fri, 10/20/23 16:40-16:50 CEST and 7:40-7:50 a.m. PST

Presentation Title: Adagrasib With or Without Cetuximab in Patients With KRASG12C-Mutated Colorectal Cancer (CRC): Analysis of Tumor Biomarkers and Genomic Alterations
Author: Meredith S. Pelster
Abstract Number: 3402
Session: Proffered Paper Session 1 – Gastrointestinal tumours, lower digestive
Presentation Date/Time: Sat, 10/21/2023 15:25-15:35 CEST and 6:25-6:35 a.m. PST

Presentation Title: SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Author: Hossein Borghaei
Abstract Number: 5049
Session: Proffered Paper session – NSCLC, metastatic
Presentation Date/Time: Fri, 10/20/23 16:00-16:10 CEST and 7:00-7:10 a.m. PST

Symposium: Near the conclusion ESMO (Free ESMO Whitepaper) 2023, Mirati is also sponsoring New Horizons in the Treatment of KRAS-Driven NSCLC and GI Cancers, an industry satellite symposium with Luis Paz-Ares, M.D., Ph.D. of Hospital Universitario 12 de Octubre, Aparna Parikh, M.D. of Mass General Cancer Center, Harvard Medical School and Keith Kerr, MB ChB, FRCPath, FRCPE of NHS Grampian. The symposium will discuss advances in targeting KRAS-driven NSCLC with a focus on the current status and future development of KRASG12C inhibitors, review the current status of targeted therapies for GI cancers and discuss the importance of timely molecular testing. The symposium will be held on October 23 from 13:00-14:30 CEST in the Valencia Auditorium, Hall 10, IFEMA Madrid.